J9298 Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg
Billable / valid for submission HCPCS Release 2026Q3
Short description: Inj nivol relatlimab 3mg/1mg
Version history
| Release | Valid from | Valid to | Description | Billable |
|---|---|---|---|---|
| 2026Q3 | 2026-07-01 | current | Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg | yes |
Related codes in J92
- J9200 Injection, floxuridine, 500 mg
- J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
- J9202 Goserelin acetate implant, per 3.6 mg
- J9203 Injection, gemtuzumab ozogamicin, 0.1 mg
- J9204 Injection, mogamulizumab-kpkc, 1 mg
- J9205 Injection, irinotecan liposome, 1 mg
- J9206 Injection, irinotecan, 20 mg
- J9207 Injection, ixabepilone, 1 mg
- J9208 Injection, ifosfamide, 1 gram
- J9209 Injection, mesna, 200 mg
- J9210 Injection, emapalumab-lzsg, 1 mg
- J9211 Injection, idarubicin hydrochloride, 5 mg
- J9213 Injection, interferon, alfa-2a, recombinant, 3 million units
- J9214 Injection, interferon, alfa-2b, recombinant, 1 million units
- J9215 Injection, interferon, alfa-n3, (human leukocyte derived), 250,000 iu
- J9216 Injection, interferon, gamma 1-b, 3 million units
- J9217 Leuprolide acetate (for depot suspension), 7.5 mg
- J9218 Leuprolide acetate, per 1 mg
- J9219 Leuprolide acetate implant, 65 mg
- J9220 Injection, indigotindisulfonate sodium, 1 mg